Stephin J. Vervoort

Stephin J. Vervoort

Auto-generated profile, based on publicly available information

Stephin J. Vervoort

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
CKConor Kearney
Conor Kearney
SVStephin J. Vervoort
Stephin J. Vervoort
SHSimon J. Hogg
Simon J. Hogg
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
AFAndrew J. Freeman
Andrew J. Freeman
JOJane Oliaro
Jane Oliaro
Immunotherapy has revolutionized outcomes for cancer patients, but the mechanisms of resistance remain poorly defined. We used a series of whole-genome clustered regularly interspaced short palindromic repeat (CRISPR)–based screens performed in vitro and in vivo to identify mechanisms of tumor immune evasion from cytotoxic lymphocytes [CD8+ T cells and natural killer (NK) cells]. Deletion of key genes within the tumor necrosis factor (TNF) signaling, interferon-γ (IFN-γ) signaling, and antigen presentation pathways provided protection of tumor cells from CD8+ T cell–mediated killing and blunted antitumor immune responses in vivo. Deletion of a number of genes in the TNF pathway also emerged as the key mechanism of immune evasion from primary NK cells. Our screens also identified that the metabolic protein 2-aminoethanethiol dioxygenase (Ado) modulates sensitivity to TNF-mediated killing by cytotoxic lymphocytes and is required for optimal control of tumors in vivo. Remarkably, we found that tumors delete the same genes when exposed to perforin-deficient CD8+ T cells, demonstrating that the dominant immune evasion strategy used by tumor cells is acquired resistance to T cell–derived cytokine-mediated antitumor effects. We demonstrate that TNF-mediated bystander killing is a potent T cell effector mechanism capable of killing antigen-negative tumor cells. In addition to highlighting the importance of TNF in CD8+ T cell– and NK cell–mediated killing of tumor cells, our study also provides a comprehensive picture of the roles of the TNF, IFN, and antigen presentation pathways in immune-mediated tumor surveillance.

17 May 2021 in Cell
Verified
Journal Article
Closed access
SVStephin J. Vervoort
Stephin J. Vervoort
SWSarah A. Welsh
Sarah A. Welsh
JDJennifer R. Devlin
Jennifer R. Devlin
EBElisa Barbieri
Elisa Barbieri
DKDeborah A. Knight
Deborah A. Knight
RJRicky W. Johnstone
Ricky W. Johnstone

1 May 2021 in Molecular Cell
Verified
Journal Article
Closed access
SHSimon J Hogg
Simon J Hogg
OMOlga Motorna
Olga Motorna
LCLeonie A Cluse
Leonie A Cluse
TJTimothy M Johanson
Timothy M Johanson
HCHannah D Coughlan
Hannah D Coughlan
RJRicky W Johnstone
Ricky W Johnstone

1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
ZFZheng Fan
Zheng Fan
JDJennifer R. Devlin
Jennifer R. Devlin
SHSimon J. Hogg
Simon J. Hogg
MDMaria A. Doyle
Maria A. Doyle
PHPaul F. Harrison
Paul F. Harrison
RJRicky W. Johnstone
Ricky W. Johnstone
CDK12 and CDK13 regulate POLII elongation rate and processivity and influence the selection of transcription termination sites.

14 May 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ELemily lelliott
emily lelliott
IKIsabella Y. Kong
Isabella Y. Kong
MZMagnus Zethoven
Magnus Zethoven
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
LMLuciano G. Martelotto
Luciano G. Martelotto
SVStephin J. Vervoort
Stephin J. Vervoort
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical success of these inhibitors is largely attributed to well-defined tumor-intrinsic cytostatic mechanisms, whereas their emerging role as immunomodulatory agents is less understood. Using integrated epigenomic, transcriptomic, and proteomic analyses, we demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunologic T-cell memory. Short-term priming with a CDK4/6 inhibitor promoted long-term endogenous antitumor T-cell immunity in mice, enhanced the persistence and therapeutic efficacy of chimeric antigen receptor T cells, and induced a retinoblastoma-dependent T-cell phenotype supportive of favorable responses to immune checkpoint blockade in patients with melanoma. Together, these mechanistic insights significantly broaden the prospective utility of CDK4/6 inhibitors as clinical tools to boost antitumor T-cell immunity. Significance: Immunologic memory is critical for sustained antitumor immunity. Our discovery that CDK4/6 inhibitors drive T-cell memory fate commitment sheds new light on their clinical activity, which is essential for the design of clinical trial protocols incorporating these agents, particularly in combination with immunotherapy, for the treatment of cancer. This article is highlighted in the In This Issue feature, p. 2355

19 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CKConor Kearney
Conor Kearney
SVStephin J. Vervoort
Stephin J. Vervoort
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
ITIzabela Todorovski
Izabela Todorovski
ELEmily J. Lelliott
Emily J. Lelliott
RJRicky W. Johnstone
Ricky W. Johnstone
A new technology, SUGAR-seq, enables simultaneous detection of surface glycans, epitopes, transcripts, and TCR repertoire.